Workflow
ClearPoint Neuro: Macro-Induced Multiple Compression
koto_feja ClearPoint Neuro’s (NASDAQ:CLPT) fourth quarter results were strong, and the first quarter of 2024 is also shaping up well. Despite this, the stock is down significantly over the past 2 months on the back of a sizeable equity raise and interest rate fears. The last time I wrote about ClearPoint I suggested it was a buy, as the company was reasonably valued and approaching an inflection point. This still appears to be the case, with recent developments reducing uncertainty regarding the company ...